Yusheng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yusheng Zhang has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Tianqi Li
Clinical Immunology and Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China
6 shared publicationsPanpan Zhang
Clinical Immunology and Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China
5 shared publicationsJinlei Sun
Clinical Immunology and Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China
4 shared publications- Shengyun Liu
Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
4 shared publications Wenlu Hu
Clinical Immunology and Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China
4 shared publicationsFang Dong
Clinical Immunology and Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China
3 shared publications
Latest Publications
- Open Access
- 11 April 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Clinical characteristics and long-term prognosis of anti-MDA5-positive dermatomyositis: a comparative study across age groups
Objectives: Research focused on clinical differences and long-term prognosis in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (anti-MDA5+ DM) patients across age groups remains limited. This study aimed to explore the differences in the clinical manifestations and long-term mortality of anti-MDA5+ DM patients across age groups. Methods: We included 318 newly diagnosed anti-MDA5+ DM patients, recruited from June 2018 to January 2024. The median follow-up time was 22.5 months (4.5–36 months). The Cochran-Armitage test for trend (CATT) was employed to assess the statistical significance of changes in the proportion of clinical characteristics across different age groups. Cox regression analysis and a nomogram model were developed to stratify the risk associated with mortality. Results: In the cohort of 318 patients, 123 (38.7%) were aged < 50 years, 124 (39.0%) were aged 50–59 years, and 71 (22.3%) were aged ≥ 60 years. Clinical manifestations and comorbidities such as cough, Pneumocystis jirovecii pneumonia (PJP), dyspnea, and rapidly progressive interstitial lung disease (RP-ILD) increased with age, while rash and arthralgia decreased. PJP was a major factor in poor prognosis, especially among older patients who were more susceptible to infection. The nomogram, the first prognostic model incorporating both age and PJP infection in anti-MDA5+ DM, demonstrated its independent and combined effects on mortality and enabled early risk stratification, providing a valuable tool for clinical decision-making. Conclusions: Clinical manifestations and laboratory parameters varied in anti-MDA5+ DM patients across different age groups. Advanced age and PJP are major factors associated with poor prognosis, with patients aged ≥ 60 years showing the highest mortality and being predominat in the high-risk group.
- 11 April 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Open AccessClinical characteristics and long-term prognosis of anti-MDA5-positive dermatomyositis: a comparative study across age groups
Objectives: Research focused on clinical differences and long-term prognosis in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (anti-MDA5+ DM) patients across age groups remains limited. This study aimed to explore the differences in the clinical manifestations and long-term mortality of anti-MDA5+ DM patients across age groups. Methods: We included 318 newly diagnosed anti-MDA5+ DM patients, recruited from June 2018 to January 2024. The median follow-up time was 22.5 months (4.5–36 months). The Cochran-Armitage test for trend (CATT) was employed to assess the statistical significance of changes in the proportion of clinical characteristics across different age groups. Cox regression analysis and a nomogram model were developed to stratify the risk associated with mortality. Results: In the cohort of 318 patients, 123 (38.7%) were aged < 50 years, 124 (39.0%) were aged 50–59 years, and 71 (22.3%) were aged ≥ 60 years. Clinical manifestations and comorbidities such as cough, Pneumocystis jirovecii pneumonia (PJP), dyspnea, and rapidly progressive interstitial lung disease (RP-ILD) increased with age, while rash and arthralgia decreased. PJP was a major factor in poor prognosis, especially among older patients who were more susceptible to infection. The nomogram, the first prognostic model incorporating both age and PJP infection in anti-MDA5+ DM, demonstrated its independent and combined effects on mortality and enabled early risk stratification, providing a valuable tool for clinical decision-making. Conclusions: Clinical manifestations and laboratory parameters varied in anti-MDA5+ DM patients across different age groups. Advanced age and PJP are major factors associated with poor prognosis, with patients aged ≥ 60 years showing the highest mortality and being predominat in the high-risk group.
- Open Access
- 17 November 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 215
Integrated metabolomic profiling identifies citrate as novel diagnostic biomarker for Anti-MDA5-Positive dermatomyositis
Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5 + DM) is a unique subtype of idiopathic inflammatory myopathy (IIM) with a poorer prognosis. The immune-metabolic landscape underlying anti-MDA5 + DM pathogenesis remains poorly defined. In our study, we integrated metabolomic profiling of plasma and peripheral blood mononuclear cells (PBMCs) in anti-MDA5 + DM. This study enrolled 183 patients with IIM and 104 healthy controls (HCs), comprising a discovery cohort of 150 patients (67 anti-MDA5 + DM patients and 83 anti-MDA5- IIM patients serving as disease controls) and 71 HCs, as well as a validation cohort of 33 patients and 33 HCs. To establish a robust diagnostic model, we implemented a dual analytical approach: seven machine learning algorithms were initially employed to identify key differentially expressed metabolites (DEMs), followed by LASSO regression analysis for optimal feature selection and model construction. Decision curve analysis (DCA) was subsequently conducted to assess their clinical applicability in decision-making scenarios. DHEAS and citrate in plasma were validated using enzyme-linked immunosorbent assay (ELISA) and biochemical assay, respectively. Non-targeted metabolomic profiling of plasma identified 90DEMs distinguishing anti-MDA5 + DM patients from HCs, including 65 upregulated and 25 downregulated metabolites. Pathway enrichment analysis revealed the predominant involvement of these plasma DEMs in beta-alanine metabolism. PBMC-derived targeted metabolomics identified 41 DEMs in anti-MDA5 + DM compared with HCs, comprising 21 upregulated and 20 downregulated metabolites. The DEMs in PBMCs also mainly participated in the beta-alanine metabolism pathway. From these DEMs, DHEAS, citrate, dimethylglycine, histidine, PAGN and Melilotate were identified as candidate biomarkers in anti-MDA5 + DM. Clinically, DHEAS levels showed a negative correlation with the prevalence of rapidly progressive interstitial lung disease (RP-ILD), citrate exhibited a negative association with rash, while dimethylglycine displayed a positive association with mortality and RP-ILD. Further combined analysis showed that the expression of plasma and PBMC dehydroepiandrosterone sulfate (DHEAS) and citrate may serve as reliable diagnostic biomarkers. Finally, DHEAS and citrate exhibited concordant variation patterns in the validation cohort. Our study underscores the pivotal role of DHEAS and citrate as promising diagnostic biomarkers of IIM and anti-MDA5 + DM, respectively, providing novel insights into the pathogenic mechanism and potential therapeutic targets.
- 17 November 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 215
Open AccessIntegrated metabolomic profiling identifies citrate as novel diagnostic biomarker for Anti-MDA5-Positive dermatomyositis
Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5 + DM) is a unique subtype of idiopathic inflammatory myopathy (IIM) with a poorer prognosis. The immune-metabolic landscape underlying anti-MDA5 + DM pathogenesis remains poorly defined. In our study, we integrated metabolomic profiling of plasma and peripheral blood mononuclear cells (PBMCs) in anti-MDA5 + DM. This study enrolled 183 patients with IIM and 104 healthy controls (HCs), comprising a discovery cohort of 150 patients (67 anti-MDA5 + DM patients and 83 anti-MDA5- IIM patients serving as disease controls) and 71 HCs, as well as a validation cohort of 33 patients and 33 HCs. To establish a robust diagnostic model, we implemented a dual analytical approach: seven machine learning algorithms were initially employed to identify key differentially expressed metabolites (DEMs), followed by LASSO regression analysis for optimal feature selection and model construction. Decision curve analysis (DCA) was subsequently conducted to assess their clinical applicability in decision-making scenarios. DHEAS and citrate in plasma were validated using enzyme-linked immunosorbent assay (ELISA) and biochemical assay, respectively. Non-targeted metabolomic profiling of plasma identified 90DEMs distinguishing anti-MDA5 + DM patients from HCs, including 65 upregulated and 25 downregulated metabolites. Pathway enrichment analysis revealed the predominant involvement of these plasma DEMs in beta-alanine metabolism. PBMC-derived targeted metabolomics identified 41 DEMs in anti-MDA5 + DM compared with HCs, comprising 21 upregulated and 20 downregulated metabolites. The DEMs in PBMCs also mainly participated in the beta-alanine metabolism pathway. From these DEMs, DHEAS, citrate, dimethylglycine, histidine, PAGN and Melilotate were identified as candidate biomarkers in anti-MDA5 + DM. Clinically, DHEAS levels showed a negative correlation with the prevalence of rapidly progressive interstitial lung disease (RP-ILD), citrate exhibited a negative association with rash, while dimethylglycine displayed a positive association with mortality and RP-ILD. Further combined analysis showed that the expression of plasma and PBMC dehydroepiandrosterone sulfate (DHEAS) and citrate may serve as reliable diagnostic biomarkers. Finally, DHEAS and citrate exhibited concordant variation patterns in the validation cohort. Our study underscores the pivotal role of DHEAS and citrate as promising diagnostic biomarkers of IIM and anti-MDA5 + DM, respectively, providing novel insights into the pathogenic mechanism and potential therapeutic targets.
- Open Access
- 1 May 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 6009-6024
Shared and Distinctive Inflammation-Related Protein Profiling in Idiopathic Inflammatory Myopathy with/without Anti-MDA5 Autoantibodies
Purpose: Due to the heterogeneous nature of the diseases, treatment efficacy and prognosis vary for idiopathic inflammatory myopathy (IIM) patients with different myositis specific autoantibodies (MSAs). This study aimed to investigate the inflammation-related protein profiling of IIM patients with different MSAs. In addition, the shared and distinctive inflammation-related protein profiling in IIM with/without anti-MDA5 autoantibodies. Methods: Seventy-seven patients with IIM of different MSAs and 53 gender/age matched healthy controls (HCs) were enrolled in this study. Ninety-two inflammation-related proteins were detected by Olink proteomics. We identified differentially expressed proteins (DEPs), and performed gene set enrichment analysis and KEGG pathway analysis. In addition, correlation between DEPs and serological parameters were performed. The least absolute shrinkage and selection operator (Lasso) regression algorithm of machine learning was used to screen biomarkers related to anti-MDA5+ DM. Results: Compared with HCs, 36 inflammation-related proteins were identified as DEPs. The top 10 DEPs were CXCL10, CXCL11, CXCL9, CXCL8, S100A12, IL-6, CCL2, CCL8, IL-10 and CCL3. The inflammation-related proteins and cytokine-cytokine receptor interaction pathway were more strikingly expressed in patients with anti-MDA5+ DM patients than in anti-MDA5- IIM patients. In addition, multiple DEPs correlated with serum ferritin, KL-6, muscle enzymes. For the first time, we established that a multi-factor panel comprising CX3CL1, IL-17C, IL-18R1, CCL20, and TNF (AUC = 0.824) serves as a highly efficient diagnostic biomarker for anti-MDA5+ DM. Conclusion: Plasma profiling revealed that inflammation and inflammatory pathways were extremely elevated in patients with IIM, especially in patients with anti-MDA5 autoantibodies. The shared and distinctive inflammation-related protein signature was demonstrated in patients with/without anti-MDA5 autoantibodies. The expression of CX3CL1 was significantly higher in anti-MDA5+ DM than in patients without anti-MDA5 autoantibodies. In addition, CX3CL1 correlated with ESR, serum ferritin, CK enzymes and disease activity, indicating that CX3CL1 participated in inflammation status of anti-MDA5+ DM.
- 1 May 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 6009-6024
Open AccessShared and Distinctive Inflammation-Related Protein Profiling in Idiopathic Inflammatory Myopathy with/without Anti-MDA5 Autoantibodies
Purpose: Due to the heterogeneous nature of the diseases, treatment efficacy and prognosis vary for idiopathic inflammatory myopathy (IIM) patients with different myositis specific autoantibodies (MSAs). This study aimed to investigate the inflammation-related protein profiling of IIM patients with different MSAs. In addition, the shared and distinctive inflammation-related protein profiling in IIM with/without anti-MDA5 autoantibodies. Methods: Seventy-seven patients with IIM of different MSAs and 53 gender/age matched healthy controls (HCs) were enrolled in this study. Ninety-two inflammation-related proteins were detected by Olink proteomics. We identified differentially expressed proteins (DEPs), and performed gene set enrichment analysis and KEGG pathway analysis. In addition, correlation between DEPs and serological parameters were performed. The least absolute shrinkage and selection operator (Lasso) regression algorithm of machine learning was used to screen biomarkers related to anti-MDA5+ DM. Results: Compared with HCs, 36 inflammation-related proteins were identified as DEPs. The top 10 DEPs were CXCL10, CXCL11, CXCL9, CXCL8, S100A12, IL-6, CCL2, CCL8, IL-10 and CCL3. The inflammation-related proteins and cytokine-cytokine receptor interaction pathway were more strikingly expressed in patients with anti-MDA5+ DM patients than in anti-MDA5- IIM patients. In addition, multiple DEPs correlated with serum ferritin, KL-6, muscle enzymes. For the first time, we established that a multi-factor panel comprising CX3CL1, IL-17C, IL-18R1, CCL20, and TNF (AUC = 0.824) serves as a highly efficient diagnostic biomarker for anti-MDA5+ DM. Conclusion: Plasma profiling revealed that inflammation and inflammatory pathways were extremely elevated in patients with IIM, especially in patients with anti-MDA5 autoantibodies. The shared and distinctive inflammation-related protein signature was demonstrated in patients with/without anti-MDA5 autoantibodies. The expression of CX3CL1 was significantly higher in anti-MDA5+ DM than in patients without anti-MDA5 autoantibodies. In addition, CX3CL1 correlated with ESR, serum ferritin, CK enzymes and disease activity, indicating that CX3CL1 participated in inflammation status of anti-MDA5+ DM.
- Open Access
- 18 July 2024
- Published by Springer Nature in Research Square
Elevated serum gamma-glutamyl transferase level as a predictor of mortality in patients with anti-MDA5 antibody-positive dermatomyositis
Background Gamma-glutamyl transferase (GGT) has been identified to correlate with systemic inflammation in autoimmune diseases, while the role of GGT in anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis (MDA5 + DM) remains unknown. This study aimed to investigate the clinical and prognostic significance of serum GGT in MDA5 + DM patients. Methods Patients with MDA5 + DM admitted to the First Affiliated Hospital of Zhengzhou University between February 2019 and May 2023 were retrospectively analyzed. We compared the clinical features and prognosis between MDA5 + DM patients with elevated serum GGT levels and those with normal serum GGT levels. Cox regression analysis was performed to identify independent factors associated with mortality. Results A total of 299 MDA5 + DM patients were enrolled in this study. During the median follow-up time of 13.1(4.4–28.1) months, 153(51.2%) patients developed rapidly progressive interstitial lung disease (RP-ILD) and 75(25.1%) patients died within 6 months after disease onset. Serum GGT levels were significantly higher in the death group compared to the survival group [95(56–165) vs 45(26–90) U/L, p58U/L, n = 144). Compared with the normal GGT group, patients in the elevated GGT group had increased incidences of skin ulcer and RP-ILD, higher levels of lactate dehydrogenase (LDH), Krebs Von den Lungen-6 (KL-6), ferritin and C-reactive protein (CRP), while lower levels of albumin and lymphocyte counts. Moreover, the Kaplan–Meier survival analysis demonstrated that the cumulative survival rate was significantly lower in the elevated GGT group than that in the normal GGT group (log-rank p < 0.001). Multivariate Cox regression analysis revealed that RP-ILD, GGT>58U/L, LDH>345U/L, CRP>5mg/L and anti-Ro52 antibody positivity were independent risk factors of mortality in MDA5 + DM patients. Conclusions Elevated serum GGT level was an independent risk factor for mortality in MDA5 + DM patients. As a novel and readily available predictor, serum GGT level may help clinicians in guiding prognostic stratification and personalized treatment.
- 18 July 2024
- Published by Springer Nature in Research Square
Open AccessElevated serum gamma-glutamyl transferase level as a predictor of mortality in patients with anti-MDA5 antibody-positive dermatomyositis
Background Gamma-glutamyl transferase (GGT) has been identified to correlate with systemic inflammation in autoimmune diseases, while the role of GGT in anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis (MDA5 + DM) remains unknown. This study aimed to investigate the clinical and prognostic significance of serum GGT in MDA5 + DM patients. Methods Patients with MDA5 + DM admitted to the First Affiliated Hospital of Zhengzhou University between February 2019 and May 2023 were retrospectively analyzed. We compared the clinical features and prognosis between MDA5 + DM patients with elevated serum GGT levels and those with normal serum GGT levels. Cox regression analysis was performed to identify independent factors associated with mortality. Results A total of 299 MDA5 + DM patients were enrolled in this study. During the median follow-up time of 13.1(4.4–28.1) months, 153(51.2%) patients developed rapidly progressive interstitial lung disease (RP-ILD) and 75(25.1%) patients died within 6 months after disease onset. Serum GGT levels were significantly higher in the death group compared to the survival group [95(56–165) vs 45(26–90) U/L, p58U/L, n = 144). Compared with the normal GGT group, patients in the elevated GGT group had increased incidences of skin ulcer and RP-ILD, higher levels of lactate dehydrogenase (LDH), Krebs Von den Lungen-6 (KL-6), ferritin and C-reactive protein (CRP), while lower levels of albumin and lymphocyte counts. Moreover, the Kaplan–Meier survival analysis demonstrated that the cumulative survival rate was significantly lower in the elevated GGT group than that in the normal GGT group (log-rank p < 0.001). Multivariate Cox regression analysis revealed that RP-ILD, GGT>58U/L, LDH>345U/L, CRP>5mg/L and anti-Ro52 antibody positivity were independent risk factors of mortality in MDA5 + DM patients. Conclusions Elevated serum GGT level was an independent risk factor for mortality in MDA5 + DM patients. As a novel and readily available predictor, serum GGT level may help clinicians in guiding prognostic stratification and personalized treatment.
- 16 May 2024
- Published by Springer Nature in Inflammation
- Vol. 48 (1) , 118-132
Peripheral Blood Lymphocyte Subsets and Heterogeneity of B Cell Subsets in Patients of Idiopathic Inflammatory Myositis with Different Myositis-specific Autoantibodies
Idiopathic inflammatory myopathies (IIM) are a group of myopathies that present with muscle weakness and multiple extra-muscular manifestations, in which lymphocytes play central roles in myositis pathogenesis. This study aimed to explore the clinical characteristics of lymphocyte subsets, especially B cell subsets, in patients with IIM. Our study included 176 patients with active IIM and 210 gender/age-matched healthy controls (HCs). Compared to HCs, patients have reduced counts of T cells, B cells, and natural killer cells. In addition, B cell subsets from 153 patients with IIM and 92 HCs were characterized. Patients had a lower percentage of memory B cells and translational memory B cells, while those patients were with an elevated percentage of CD19+ B cells, plasmablast and naïve B cells compared with HCs. Moreover, to further explore the heterogeneity of B cells in IIM, patients were categorized into three clusters based on clustering analysis. Cluster 1 was dominated by CD19+ B cells, Bregs and naïve B cells, cluster 3 was dominated by memory B cells and plasmablast, and cluster 2 had the highest proportion of translational memory B cells. Notably, patients in cluster 1 presented with higher CK levels, indicating muscle damage, whereas patients in cluster 3 showed a higher incidence of chest tightness. Our study indicated that lymphopenia is a common manifestation in patients with IIM. B cell subsets are abnormally expressed and showed high heterogeneity in patients with IIM. The patients with IIM were divided into three different clusters with different percentages of chest tightness and distinct CK levels.
- 16 May 2024
- Published by Springer Nature in Inflammation
- Vol. 48 (1) , 118-132
Peripheral Blood Lymphocyte Subsets and Heterogeneity of B Cell Subsets in Patients of Idiopathic Inflammatory Myositis with Different Myositis-specific Autoantibodies
Idiopathic inflammatory myopathies (IIM) are a group of myopathies that present with muscle weakness and multiple extra-muscular manifestations, in which lymphocytes play central roles in myositis pathogenesis. This study aimed to explore the clinical characteristics of lymphocyte subsets, especially B cell subsets, in patients with IIM. Our study included 176 patients with active IIM and 210 gender/age-matched healthy controls (HCs). Compared to HCs, patients have reduced counts of T cells, B cells, and natural killer cells. In addition, B cell subsets from 153 patients with IIM and 92 HCs were characterized. Patients had a lower percentage of memory B cells and translational memory B cells, while those patients were with an elevated percentage of CD19+ B cells, plasmablast and naïve B cells compared with HCs. Moreover, to further explore the heterogeneity of B cells in IIM, patients were categorized into three clusters based on clustering analysis. Cluster 1 was dominated by CD19+ B cells, Bregs and naïve B cells, cluster 3 was dominated by memory B cells and plasmablast, and cluster 2 had the highest proportion of translational memory B cells. Notably, patients in cluster 1 presented with higher CK levels, indicating muscle damage, whereas patients in cluster 3 showed a higher incidence of chest tightness. Our study indicated that lymphopenia is a common manifestation in patients with IIM. B cell subsets are abnormally expressed and showed high heterogeneity in patients with IIM. The patients with IIM were divided into three different clusters with different percentages of chest tightness and distinct CK levels.
- Open Access
- 15 January 2024
- Published by Springer Nature in Research Square
Peripheral blood lymphocyte subsets and heterogeneity of B cell subsets in patients of idiopathic inflammatory myositis with different myositis-specific autoantibodies
Objective To explore the characteristics and clinical significance of lymphocyte subsets, especially B cell subsets in patients with idiopathic inflammatory myositis (IIM). Methods A total of 176 patients with IIM in active disease condition and 210 gender/age-matched healthy controls (HCs) were included in our study. Demographic characteristics and lymphocyte subset patterns were compared between the two groups. In addition, B cell subsets from 153 patients with IIM and 92 HCs were characterized. Based on principal component analysis (PCA) of B cell subsets, patients with IIM were classified into three different subgroups by hierarchical cluster analysis. Subsequently, demographic characteristics, antibody types and clinical characteristics were compared among the subgroups. Results Patients with IIM have reduced counts of peripheral lymphocyte subsets compared with HCs, which included T cells, B cells, and natural killer cells. Also, B cell subsets were altered in patients with IIM. The percentages of memory B cells and translational memory B cells were reduced, while CD19 + B cells, plasmablast and naïve B cells were increased. Moreover, to explore the heterogeneity of B cells in IIM patients, patients were categorized into 3 clusters based on B cell subset clustering analysis. Cluster 1 was dominated by CD19 + B cells, Bregs and Naïve B cells, cluster 3 was dominated by Memory B cells and plasmablast, and the proportion of B cell subsets in cluster 2 was in between. Notably, the patients of cluster 1 had the highest proportion of anti-TIF1-γ antibodies, whereas cluster 3 showed an elevated proportion of anti-MDA5 + antibodies. Chest tightness was more prominent in clusters 2 and 3 compared to clusters 1. Moreover, B cell subsets were correlated with multiple laboratory parameters. Conclusion Our study indicated that lymphopenia is a common manifestation in patients with IIM. B cell subsets are abnormally expressed and showed high heterogeneity in patients with IIM by cluster analysis. The clinical characteristics and laboratory parameters differed among the three clusters.
- 15 January 2024
- Published by Springer Nature in Research Square
Open AccessPeripheral blood lymphocyte subsets and heterogeneity of B cell subsets in patients of idiopathic inflammatory myositis with different myositis-specific autoantibodies
Objective To explore the characteristics and clinical significance of lymphocyte subsets, especially B cell subsets in patients with idiopathic inflammatory myositis (IIM). Methods A total of 176 patients with IIM in active disease condition and 210 gender/age-matched healthy controls (HCs) were included in our study. Demographic characteristics and lymphocyte subset patterns were compared between the two groups. In addition, B cell subsets from 153 patients with IIM and 92 HCs were characterized. Based on principal component analysis (PCA) of B cell subsets, patients with IIM were classified into three different subgroups by hierarchical cluster analysis. Subsequently, demographic characteristics, antibody types and clinical characteristics were compared among the subgroups. Results Patients with IIM have reduced counts of peripheral lymphocyte subsets compared with HCs, which included T cells, B cells, and natural killer cells. Also, B cell subsets were altered in patients with IIM. The percentages of memory B cells and translational memory B cells were reduced, while CD19 + B cells, plasmablast and naïve B cells were increased. Moreover, to explore the heterogeneity of B cells in IIM patients, patients were categorized into 3 clusters based on B cell subset clustering analysis. Cluster 1 was dominated by CD19 + B cells, Bregs and Naïve B cells, cluster 3 was dominated by Memory B cells and plasmablast, and the proportion of B cell subsets in cluster 2 was in between. Notably, the patients of cluster 1 had the highest proportion of anti-TIF1-γ antibodies, whereas cluster 3 showed an elevated proportion of anti-MDA5 + antibodies. Chest tightness was more prominent in clusters 2 and 3 compared to clusters 1. Moreover, B cell subsets were correlated with multiple laboratory parameters. Conclusion Our study indicated that lymphopenia is a common manifestation in patients with IIM. B cell subsets are abnormally expressed and showed high heterogeneity in patients with IIM by cluster analysis. The clinical characteristics and laboratory parameters differed among the three clusters.
- 25 September 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-9
DFGC-VRA: DeepFake Game Competition on Visual Realism Assessment
This paper presents the summary report on the DeepFake Game Competition on Visual Realism Assessment (DFGC-VRA). Deep-learning based face-swap videos, also known as deepfakes, are becoming more and more realistic and deceiving. The malicious usage of these face-swap videos has caused wide concerns. There is a ongoing deepfake game between its creators and detectors, with the human in the loop. The research community has been focusing on the automatic detection of these fake videos, but the assessment of their visual realism, as perceived by human eyes, is still an unexplored dimension. Visual realism assessment, or VRA, is essential for assessing the potential impact that may be brought by a specific face-swap video, and it is also useful as a quality metric to compare different face-swap methods. This is the third edition of DFGC competitions, which focuses on the new visual realism assessment topic, different from previous ones that compete creators versus detectors. With this competition, we conduct a comprehensive study of the SOTA performance on the new task. We also release our MindSpore codes to further facilitate research in this field (https://github.com/bomb2peng/DFGC-VRA-benckmark).
- 25 September 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-9
DFGC-VRA: DeepFake Game Competition on Visual Realism Assessment
This paper presents the summary report on the DeepFake Game Competition on Visual Realism Assessment (DFGC-VRA). Deep-learning based face-swap videos, also known as deepfakes, are becoming more and more realistic and deceiving. The malicious usage of these face-swap videos has caused wide concerns. There is a ongoing deepfake game between its creators and detectors, with the human in the loop. The research community has been focusing on the automatic detection of these fake videos, but the assessment of their visual realism, as perceived by human eyes, is still an unexplored dimension. Visual realism assessment, or VRA, is essential for assessing the potential impact that may be brought by a specific face-swap video, and it is also useful as a quality metric to compare different face-swap methods. This is the third edition of DFGC competitions, which focuses on the new visual realism assessment topic, different from previous ones that compete creators versus detectors. With this competition, we conduct a comprehensive study of the SOTA performance on the new task. We also release our MindSpore codes to further facilitate research in this field (https://github.com/bomb2peng/DFGC-VRA-benckmark).
- 9 May 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (8) , 2145-2154
Plasma proteomic profiling reveals KRT19 could be a potential biomarker in patients with anti-MDA5+ dermatomyositis
Objective To investigate the immune response–related protein profiling in plasma of patients with idiopathic inflammatory myopathies (IIMs), especially in anti-MDA5+ dermatomyositis (DM). Methods A total of 166 IIM patients and 107 healthy controls (HCs) were enrolled in our study. Ninety-two plasma immune response–related proteins were detected by Olink proteomics in 36 IIM patients and 25 HCs. The expression of plasma KRT19 was validated in another 130 IIM patients, 82 HCs, and 55 other rheumatic diseases. Results A total of 46 differentially expressed proteins were detected, including 12 upregulated proteins and 34 downregulated proteins in IIM patients compared with HCs. Pathway analysis revealed lactoferrin danger signal response pathway, TLR4 signaling and tolerance, infection, and IL-10 signaling pathway were activated. The immune response–related protein profiling significantly altered in anti-MDA5+ DM patients, with LAMP3, HSD11B1, and KRT19 significantly increased, while SH2D1A, ITGA11, TRIM21, CD28, ITGB6, and HEXIM1 tremendously decreased. In addition, KRT19 was significantly increased in IIM patients, especially in anti-MDA5+ DM patients with the diagnostic value of a significant area under the ROC curve of 0.881. Conclusion Immune response–related proteins are significantly altered in patients with anti-MDA5+ DM patients. KRT19 could be a potential biomarker for anti-MDA5+ DM patients. Key Points • What is already known on this topic? Anti-MDA5+ DM is a distinctive subtype of IIM. Plasma immune response–related proteins panel needs to be investigated. • What this study adds? Plasma protein profiling of immune response–related proteins significantly altered in patients with idiopathic inflammatory myopathies (IIM), especially in anti-MDA5+ DM patients. • How this study might affect research, practice, or policy? KRT19 could be a potential biomarker in patients with anti-MDA5+ dermatomyositis.
- 9 May 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (8) , 2145-2154
Plasma proteomic profiling reveals KRT19 could be a potential biomarker in patients with anti-MDA5+ dermatomyositis
Objective To investigate the immune response–related protein profiling in plasma of patients with idiopathic inflammatory myopathies (IIMs), especially in anti-MDA5+ dermatomyositis (DM). Methods A total of 166 IIM patients and 107 healthy controls (HCs) were enrolled in our study. Ninety-two plasma immune response–related proteins were detected by Olink proteomics in 36 IIM patients and 25 HCs. The expression of plasma KRT19 was validated in another 130 IIM patients, 82 HCs, and 55 other rheumatic diseases. Results A total of 46 differentially expressed proteins were detected, including 12 upregulated proteins and 34 downregulated proteins in IIM patients compared with HCs. Pathway analysis revealed lactoferrin danger signal response pathway, TLR4 signaling and tolerance, infection, and IL-10 signaling pathway were activated. The immune response–related protein profiling significantly altered in anti-MDA5+ DM patients, with LAMP3, HSD11B1, and KRT19 significantly increased, while SH2D1A, ITGA11, TRIM21, CD28, ITGB6, and HEXIM1 tremendously decreased. In addition, KRT19 was significantly increased in IIM patients, especially in anti-MDA5+ DM patients with the diagnostic value of a significant area under the ROC curve of 0.881. Conclusion Immune response–related proteins are significantly altered in patients with anti-MDA5+ DM patients. KRT19 could be a potential biomarker for anti-MDA5+ DM patients. Key Points • What is already known on this topic? Anti-MDA5+ DM is a distinctive subtype of IIM. Plasma immune response–related proteins panel needs to be investigated. • What this study adds? Plasma protein profiling of immune response–related proteins significantly altered in patients with idiopathic inflammatory myopathies (IIM), especially in anti-MDA5+ DM patients. • How this study might affect research, practice, or policy? KRT19 could be a potential biomarker in patients with anti-MDA5+ dermatomyositis.
- Open Access
- 1 August 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 140, 111695
Corrigendum to ‘Proteomic changes in the hippocampus and motor cortex in a rat model of cerebral palsy: Effects of topical treatment’ [Biomed. Pharmacother. 133 (2021) 110844]
- 1 August 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 140, 111695
Open AccessCorrigendum to ‘Proteomic changes in the hippocampus and motor cortex in a rat model of cerebral palsy: Effects of topical treatment’ [Biomed. Pharmacother. 133 (2021) 110844]
- 1 February 2018
- Published by Elsevier in Neuroscience
- Vol. 371, 469-483
Proteomic Profiling of Brain and Testis Reveals the Diverse Changes in Ribosomal Proteins in fmr1 Knockout Mice
- 1 February 2018
- Published by Elsevier in Neuroscience
- Vol. 371, 469-483
Proteomic Profiling of Brain and Testis Reveals the Diverse Changes in Ribosomal Proteins in fmr1 Knockout Mice